Journal of Integrative Oncology

Long-term Follow-up of Pegylated Liposomal Doxorubicin and Oxaliplatin in Recurrent Ovarian Cancer

Abstract

Francesco Recchia, Giampiero Candeloro and Silvio Rea

Oxaliplatin (LOHP) and pegylated liposomal doxorubicin (PLD) are active single agents in recurrent ovarian cancer (ROC). In this phase II study we explored safety and activity of combined LOHP and PLD in the treatment of ROC. Eligible patients had had disease recurrence following a paclitaxel/ carboplatin regimen or following cisplatinum or non-platinum-based second line chemotherapy. Other eligibility criteria were a performance status ≤ 2 and a life expectancy > 3 months. Treatment consisted of 120 mg/m2 LOHP and 40 mg/m2 PLD, given over 2 days, every 3 weeks. Forty-six patients with ROC were entered into the study between 10/2001 and 10/2005; 67.5% of patients were platinum-sensitive. Toxicity was moderate, with grade 3 or 4 neutropenia in 2% of patients, and grade 2 PPE in 7% of patients. Overall response rate was 67.5%. Median progression-free survival (PFS) was 27.5 months, while median overall survival was 44 months. We conclude that LOHP and PLD are active in ROC, and can be safely administered in pre-treated patients